Histone deacetylase and DNA methyltransferase in human prostate cancer - PubMed (original) (raw)
. 2001 Sep 28;287(3):705-13.
doi: 10.1006/bbrc.2001.5639.
Affiliations
- PMID: 11563853
- DOI: 10.1006/bbrc.2001.5639
Histone deacetylase and DNA methyltransferase in human prostate cancer
S K Patra et al. Biochem Biophys Res Commun. 2001.
Abstract
CpG island hypermethylation and chromatin remodeling play important roles in repression of various genes during malignant transformation. We hypothesized that histone deacetylases (HDACs) and DNA methyltransferases (DNMTase) are associated with prostate cancer and we examined the enzyme activity, gene, and protein expression of HDAC1 and DNMT1 in cell lines and tissues. We found that DNMTase and HDACs activities were two- to threefold higher in cell lines compared to benign prostatic hyperplasia (BPH-1) cell line. Treatment of cells with 5-aza-2'-deoxycytidine decreased the activity of HDAC and DNMTase. The mRNA expression of these genes in BPH-1 cells and BPH tissues was lower than that in prostate cancer cells and tissues. HDAC1 and DNMT1 protein expression was higher in prostate cancer compared to BPH. This is the first report to demonstrate that DNMT1 and HDAC1 levels are up-regulated in prostate cancer compared to BPH, suggesting their roles in inactivation of various genes, by DNA-methylation-induced chromatin-remodeling, in prostate cancer.
Copyright 2001 Academic Press.
Similar articles
- Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, Terashima M, Fujime M, Igawa M, Dahiya R. Ogishima T, et al. Clin Cancer Res. 2005 Feb 1;11(3):1028-36. Clin Cancer Res. 2005. PMID: 15709168 - CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
Zhao H, Shiina H, Greene KL, Li LC, Tanaka Y, Kishi H, Igawa M, Kane CJ, Carroll P, Dahiya R. Zhao H, et al. Cancer. 2005 Jul 1;104(1):44-52. doi: 10.1002/cncr.21135. Cancer. 2005. PMID: 15895377 - Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells.
Zhu WG, Dai Z, Ding H, Srinivasan K, Hall J, Duan W, Villalona-Calero MA, Plass C, Otterson GA. Zhu WG, et al. Oncogene. 2001 Nov 22;20(53):7787-96. doi: 10.1038/sj.onc.1204970. Oncogene. 2001. PMID: 11753657 - DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP, Harya NS, Hutzley J, Bacich DJ, Monzon FA, Chandran U, Dhir R, O'Keefe DS. Kelavkar UP, et al. Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):185-97. doi: 10.1016/j.prostaglandins.2006.05.015. Epub 2006 Jul 11. Prostaglandins Other Lipid Mediat. 2007. PMID: 17164146 - DNA methylation in development and disease: an overview for prostate researchers.
Joseph DB, Strand DW, Vezina CM. Joseph DB, et al. Am J Clin Exp Urol. 2018 Dec 20;6(6):197-218. eCollection 2018. Am J Clin Exp Urol. 2018. PMID: 30697577 Free PMC article. Review.
Cited by
- Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.
Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E. Myzak MC, et al. Carcinogenesis. 2006 Apr;27(4):811-9. doi: 10.1093/carcin/bgi265. Epub 2005 Nov 9. Carcinogenesis. 2006. PMID: 16280330 Free PMC article. - Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors.
Sedky NK, Hamdan AA, Emad S, Allam AL, Ali M, Tolba MF. Sedky NK, et al. Clin Transl Oncol. 2022 Jul;24(7):1262-1273. doi: 10.1007/s12094-022-02779-x. Epub 2022 Jan 23. Clin Transl Oncol. 2022. PMID: 35066777 Review. - Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.
Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Marquard L, et al. Histopathology. 2008 Sep;53(3):267-77. doi: 10.1111/j.0309-0167.2008.03109.x. Histopathology. 2008. PMID: 18671804 Free PMC article. - Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.
Iwahashi S, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Sugimoto K, Saito Y. Iwahashi S, et al. Int J Clin Oncol. 2011 Dec;16(6):671-8. doi: 10.1007/s10147-011-0246-y. Epub 2011 May 10. Int J Clin Oncol. 2011. PMID: 21556798 - Promoter de-methylation of cyclin D2 by sulforaphane in prostate cancer cells.
Hsu A, Wong CP, Yu Z, Williams DE, Dashwood RH, Ho E. Hsu A, et al. Clin Epigenetics. 2011;3(1):3. doi: 10.1186/1868-7083-3-3. Epub 2011 Oct 26. Clin Epigenetics. 2011. PMID: 22303414 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous